WHO and the European Commission expand partnership to combat antimicrobial resistance

The World Health Organization (WHO) and the European Commission have expanded their strategic partnership to combat antimicrobial resistance (AMR) through a new €3.5 million agreement under the EU4Health programme, strengthening global efforts to address one of the most urgent public-health threats. The funding will support WHO in accelerating research and development of new antibiotics, antifungals and non-traditional therapies, while also improving sustainable and equitable access to both existing and novel antimicrobials worldwide through initiatives such as SECURE, co-led with GARDP. Building on their collaboration launched in 2022, the partnership aligns health security, innovation and access, reinforcing the shared commitment of the EU and WHO to slow the spread of AMR and safeguard the effectiveness of life-saving treatments.